trending Market Intelligence /marketintelligence/en/news-insights/trending/az9G5YE5xT1INRcQmkSJQA2 content esgSubNav
In This List

Heat Biologics closes common stock offering

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Heat Biologics closes common stock offering

Heat Biologics Inc. closed its underwritten public offering of 5 million common shares at 80 cents apiece.

The offering generated gross proceeds of $4 million.

Underwriters in the transaction have the option to buy up to an additional 750,000 shares.

Heat Biologics plans to use the net proceeds to fund preclinical and clinical programs; for working capital and general corporate purposes; and to acquire, license or invest in complementary businesses, technologies, product candidates or other intellectual property.

Aegis Capital Corp. acted as the sole book-running manager for the offering.